REFERENCES
1. Li P, Ding Z, Feng Y, et al. Global, regional, and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries/territories in 2022. Sci Bull. 2026;71:838-49.
2. Karageorgos SA, Stratakou S, Koulentaki M, et al. Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study. Ann Gastroenterol. 2017;30:357-63.
3. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006;26:1175-86.
4. Kupffer C. Ueber sternzellen der leber: briefliche mittheilung an Prof. Waldeyer. Archiv f mikrosk Anat. 1876;12:353-8.
5. Wake K. Karl Wilhelm Kupffer and his contributions to modern hepatology. Comp Hepatol. 2004;3:S2.
6. Ueber intravasculäre Zellen in den Blutcapillaren der Leberacini. Arch f mikrosk Anat. 1899;55:420-6.
7. Underhill DM, Gordon S, Imhof BA, Núñez G, Bousso P. Élie Metchnikoff (1845-1916): celebrating 100 years of cellular immunology and beyond. Nat Rev Immunol. 2016;16:651-6.
8. Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123-47.
9. Aegerter H, Kulikauskaite J, Crotta S, et al. Influenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection. Nat Immunol. 2020;21:145-57.
10. Remmerie A, Martens L, Thoné T, et al. Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver. Immunity. 2020;53:641-57.e14.
11. Remmerie A, Martens L, Scott CL. Macrophage subsets in obesity, aligning the liver and adipose tissue. Front Endocrinol. 2020;11:259.
12. Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol. 2016;13:316-27.
14. Ydens E, Amann L, Asselbergh B, et al. Profiling peripheral nerve macrophages reveals two macrophage subsets with distinct localization, transcriptome and response to injury. Nat Neurosci. 2020;23:676-89.
15. Morgantini C, Jager J, Li X, et al. Liver macrophages regulate systemic metabolism through non-inflammatory factors. Nat Metab. 2019;1:445-59.
16. Perdiguero EG, Geissmann F. The development and maintenance of resident macrophages. Nat Immunol. 2016;17:2-8.
18. Gola A, Dorrington MG, Speranza E, et al. Commensal-driven immune zonation of the liver promotes host defence. Nature. 2021;589:131-6.
19. Ben-Moshe S, Veg T, Manco R, et al. The spatiotemporal program of zonal liver regeneration following acute injury. Cell Stem Cell. 2022;29:973-89.e10.
20. Feng D, Guan Y, Wang Y, Maccioni L, Mackowiak B, Gao B. Characterisation of macrophages in healthy and diseased livers in mice: identification of necrotic lesion-associated macrophages. eGastroenterology. 2025;3:e100189.
21. Tran S, Baba I, Poupel L, et al. Impaired kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis. Immunity. 2020;53:627-40.e5.
22. Daemen S, Gainullina A, Kalugotla G, et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep. 2021;34:108626.
23. Rolot M, M Dougall A, Javaux J, et al. Recruitment of hepatic macrophages from monocytes is independent of IL-4Rα but is associated with ablation of resident macrophages in schistosomiasis. Eur J Immunol. 2019;49:1067-81.
24. Seidman JS, Troutman TD, Sakai M, et al. Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis. Immunity. 2020;52:1057-74.e7.
25. Fan X, Lu P, Cui XH, et al. Repopulating Kupffer cells originate directly from hematopoietic stem cells. Stem Cell Res Ther. 2023;14:351.
26. Guillot A, Tacke F. Liver macrophages: old dogmas and new insights. Hepatol Commun. 2019;3:730-43.
27. Sakai M, Troutman TD, Seidman JS, et al. Liver-derived signals sequentially reprogram myeloid enhancers to initiate and maintain Kupffer cell identity. Immunity. 2019;51:655-70.e8.
28. Liu Z, Gu Y, Chakarov S, et al. Fate mapping via Ms4a3-expression history traces monocyte-derived cells. Cell. 2019;178:1509-25.e19.
29. Guilliams M, Bonnardel J, Haest B, et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell. 2022;185:379-96.e38.
31. Miyamoto Y, Kikuta J, Matsui T, et al. Periportal macrophages protect against commensal-driven liver inflammation. Nature. 2024;629:901-9.
32. Blériot C, Barreby E, Dunsmore G, et al. A subset of Kupffer cells regulates metabolism through the expression of CD36. Immunity. 2021;54:2101-16.e6.
33. De Simone G, Andreata F, Bleriot C, et al. Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming. Immunity. 2021;54:2089-100.e8.
34. Hume DA, Offermanns S, Bonnavion R. Contamination of isolated mouse Kupffer cells with liver sinusoidal endothelial cells. Immunity. 2022;55:1139-40.
35. Beattie L, Sawtell A, Mann J, et al. Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions. J Hepatol. 2016;65:758-68.
36. Lee KJ, Kim MY, Han YH. Roles of heterogenous hepatic macrophages in the progression of liver diseases. BMB Rep. 2022;55:166-74.
37. Guo W, Li Z, Anagnostopoulos G, et al. Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease. Immunity. 2024;57:2310-27.e6.
38. Scott CL, Zheng F, De Baetselier P, et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun. 2016;7:10321.
39. Bonnardel J, T’Jonck W, Gaublomme D, et al. Stellate cells, hepatocytes, and endothelial cells imprint the Kupffer cell identity on monocytes colonizing the liver macrophage niche. Immunity. 2019;51:638-54.e9.
40. Elchaninov A, Vishnyakova P, Kuznetsova M, et al. Mimicking the cellular environment does not cause monocyte-derived macrophages to become phenotypically similar to Kupffer cells. Immunol Cell Biol. 2024;102:381-95.
41. Soysa R, Lampert S, Yuen S, et al. Fetal origin confers radioresistance on liver macrophages via p21(cip1/WAF1). J Hepatol. 2019;71:553-62.
42. Iannacone M, Blériot C, Andreata F, et al. Response to contamination of isolated mouse Kupffer cells with liver sinusoidal endothelial cells. Immunity. 2022;55:1141-2.
43. Ni M, Zhang J, Sosa R, et al. T-cell immunoglobulin and mucin domain-containing protein-4 is critical for Kupffer cell homeostatic function in the activation and resolution of liver ischemia reperfusion injury. Hepatology. 2021;74:2118-32.
44. Woolbright BL, Jaeschke H. The impact of sterile inflammation in acute liver injury. J Clin Transl Res. 2017;3:170-88.
45. Zwicker C, Bujko A, Scott CL. Hepatic macrophage responses in inflammation, a function of plasticity, heterogeneity or both? Front Immunol. 2021;12:690813.
46. MacParland SA, Liu JC, Ma XZ, et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat Commun. 2018;9:4383.
47. Aizarani N, Saviano A, Sagar, et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature. 2019;572:199-204.
48. Ramachandran P, Dobie R, Wilson-Kanamori JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 2019;575:512-8.
49. Andrews TS, Atif J, Liu JC, et al. Single-cell, single-nucleus, and spatial RNA sequencing of the human liver identifies cholangiocyte and mesenchymal heterogeneity. Hepatol Commun. 2022;6:821-40.
50. Ramachandran P. Zonal control of liver inflammation is orchestrated by periportal Kupffer cells. J Hepatol. 2025;82:546-7.
51. Wu X, Hollingshead N, Roberto J, et al. Human liver macrophage subsets defined by CD32. Front Immunol. 2020;11:2108.
52. Martrus G, Goebels H, Langeneckert AE, et al. CD49a expression identifies a subset of intrahepatic macrophages in humans. Front Immunol. 2019;10:1247.
53. Fabre T, Barron AMS, Christensen SM, et al. Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation. Sci Immunol. 2023;8:eadd8945.
54. Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol. 2021;18:45-56.
55. Lee WY, Moriarty TJ, Wong CH, et al. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol. 2010;11:295-302.
56. Gorgani NN, He JQ, Katschke KJ Jr, et al. Complement receptor of the Ig superfamily enhances complement-mediated phagocytosis in a subpopulation of tissue resident macrophages. J Immunol. 2008;181:7902-8.
57. Chaudhry S, Emond J, Griesemer A. Immune cell trafficking to the liver. Transplantation. 2019;103:1323-37.
58. Zhang JX, Yang Y, Huang H, et al. TNF-α/TNFR1 regulates the polarization of Kupffer cells to mediate trichloroethylene-induced liver injury. Ecotoxicol Environ Saf. 2022;230:113141.
59. Strizova Z, Benesova I, Bartolini R, et al. M1/M2 macrophages and their overlaps - myth or reality? Clin Sci. 2023;137:1067-93.
60. Sanin DE, Ge Y, Marinkovic E, et al. A common framework of monocyte-derived macrophage activation. Sci Immunol. 2022;7:eabl7482.
61. Oshi M, Tokumaru Y, Asaoka M, et al. M1 macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer. Sci Rep. 2020;10:16554.
62. Cao F, Liu Y, Cheng Y, Wang Y, He Y, Xu Y. Multi-omics characteristics of tumor-associated macrophages in the tumor microenvironment of gastric cancer and their exploration of immunotherapy potential. Sci Rep. 2023;13:18265.
63. Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun. 2022;42:1112-40.
64. Keirsse J, Van Damme H, Geeraerts X, Beschin A, Raes G, Van Ginderachter JA. The role of hepatic macrophages in liver metastasis. Cell Immunol. 2018;330:202-15.
65. Heymann F, Peusquens J, Ludwig-Portugall I, et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015;62:279-91.
66. Doherty DG. Immunity, tolerance and autoimmunity in the liver: a comprehensive review. J Autoimmun. 2016;66:60-75.
67. Breous E, Somanathan S, Vandenberghe LH, Wilson JM. Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology. 2009;50:612-21.
68. Gong J, Tu W, Liu J, Tian D. Hepatocytes: a key role in liver inflammation. Front Immunol. 2022;13:1083780.
69. Campana L, Esser H, Huch M, Forbes S. Liver regeneration and inflammation: from fundamental science to clinical applications. Nat Rev Mol Cell Biol. 2021;22:608-24.
72. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol. 2013;3:785-97.
73. Li X, Hollingshead N, Lampert S, et al. A conserved pathway of transdifferentiation in murine Kupffer cells. Eur J Immunol. 2021;51:2452-63.
74. Gaul S, Leszczynska A, Alegre F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol. 2021;74:156-67.
75. Knorr J, Kaufmann B, Inzaugarat ME, et al. Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Hepatology. 2023;77:1968-82.
76. Gan C, Cai Q, Tang C, Gao J. Inflammasomes and pyroptosis of liver cells in liver fibrosis. Front Immunol. 2022;13:896473.
77. Vonderlin J, Chavakis T, Sieweke M, Tacke F. The multifaceted roles of macrophages in NAFLD pathogenesis. Cell Mol Gastroenterol Hepatol. 2023;15:1311-24.
78. Guillot A, Winkler M, Silva Afonso M, et al. Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression. Hepatology. 2023;78:150-66.
79. Su SB, Qin SY, Xian XL, et al. Interleukin-22 regulating Kupffer cell polarization through STAT3/Erk/Akt crosstalk pathways to extenuate liver fibrosis. Life Sci. 2021;264:118677.
80. Sakai Y, Chen G, Ni Y, et al. DPP-4 inhibition with anagliptin reduces lipotoxicity-induced insulin resistance and steatohepatitis in male mice. Endocrinology. 2020;161:bqaa139.
81. Cao S, Liu M, Sehrawat TS, Shah VH. Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol. 2021;18:630-47.
82. She S, Ren L, Chen P, et al. Functional roles of chemokine receptor CCR2 and its ligands in liver disease. Front Immunol. 2022;13:812431.
83. Gao J, Wei B, Liu M, et al. Endothelial p300 promotes portal hypertension and hepatic fibrosis through C-C motif chemokine ligand 2-mediated angiocrine signaling. Hepatology. 2021;73:2468-83.
84. Guo Y, Zhao C, Dai W, et al. C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape. Int J Biol Sci. 2023;19:2572-87.
85. Lefere S, Devisscher L, Tacke F. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opin Investig Drugs. 2020;29:89-92.
86. Peiseler M, Araujo David B, Zindel J, et al. Kupffer cell-like syncytia replenish resident macrophage function in the fibrotic liver. Science. 2023;381:eabq5202.
87. Arteel GE. When is a Kupffer cell not a Kupffer cell? Novel insight into macrophage fate and function in hepatic fibrosis. J Leukoc Biol. 2024;115:415-6.
88. Sun K, Xu L, Jing Y, et al. Autophagy-deficient Kupffer cells promote tumorigenesis by enhancing mtROS-NF-κB-IL1α/β-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis. Cancer Lett. 2017;388:198-207.
89. Ilyas G, Zhao E, Liu K, et al. Macrophage autophagy limits acute toxic liver injury in mice through down regulation of interleukin-1β. J Hepatol. 2016;64:118-27.
90. Chen L, Kong D, Xia S, et al. Crosstalk between autophagy and innate immunity: a pivotal role in hepatic fibrosis. Front Pharmacol. 2022;13:891069.
91. Lodder J, Denaës T, Chobert MN, et al. Macrophage autophagy protects against liver fibrosis in mice. Autophagy. 2015;11:1280-92.
92. Zhu J, Zhang W, Zhang L, et al. IL-7 suppresses macrophage autophagy and promotes liver pathology in Schistosoma japonicum-infected mice. J Cell Mol Med. 2018;22:3353-63.
93. Matuz-Mares D, Vázquez-Meza H, Vilchis-Landeros MM. NOX as a therapeutic target in liver disease. Antioxidants. 2022;11:2038.
94. Herranz-Itúrbide M, Peñuelas-Haro I, Espinosa-Sotelo R, Bertran E, Fabregat I. The TGF-β/NADPH oxidases axis in the regulation of liver cell biology in health and disease. Cells. 2021;10:2312.
95. Nairz M, Theurl I, Swirski FK, Weiss G. “Pumping iron”-how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch. 2017;469:397-418.
96. Scott CL, Guilliams M. The role of Kupffer cells in hepatic iron and lipid metabolism. J Hepatol. 2018;69:1197-9.
97. Deppermann C, Kratofil RM, Peiseler M, et al. Macrophage galactose lectin is critical for Kupffer cells to clear aged platelets. J Exp Med. 2020;217:e20190723.
99. Gao H, Jin Z, Bandyopadhyay G, et al. MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH. Cell Metab. 2022;34:978- 90.e4.
100. Coelho I, Duarte N, Macedo MP, Penha-Gonçalves C. Insights into macrophage/monocyte-endothelial cell crosstalk in the liver: a role for trem-2. J Clin Med. 2021;10:1248.
101. Gibert-Ramos A, Andrés-Rozas M, Pastó R, Alfaro-Retamero P, Guixé-Muntet S, Gracia-Sancho J. Sinusoidal communication in chronic liver disease. Clin Mol Hepatol. 2025;31:32-55.
102. Li W, Chang N, Li L. Heterogeneity and function of kupffer cells in liver injury. Front Immunol. 2022;13:940867.
103. Elchaninov A, Vishnyakova P, Menyailo E, Sukhikh G, Fatkhudinov T. An eye on Kupffer cells: development, phenotype and the macrophage niche. Int J Mol Sci. 2022;23:9868.
104. Musrati MA, De Baetselier P, Movahedi K, Van Ginderachter JA. Ontogeny, functions and reprogramming of Kupffer cells upon infectious disease. Front Immunol. 2023;14:1238452.
105. Nusse Y, Kubes P. Liver macrophages: development, dynamics, and functions. Cell Mol Immunol. 2025;22:1178-89.
106. Cao M, Wang Z, Lan W, et al. The roles of tissue resident macrophages in health and cancer. Exp Hematol Oncol. 2024;13:3.
107. Vogel A, Weichhart T. Tissue-resident macrophages - early passengers or drivers in the tumor niche? Curr Opin Biotechnol. 2023;83:102984.
108. Mulder K, Patel AA, Kong WT, et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity. 2021;54:1883-900.e5.
109. Lazarov T, Juarez-Carreño S, Cox N, Geissmann F. Physiology and diseases of tissue-resident macrophages. Nature. 2023;618:698-707.
110. Elfstrum AK, Bapat AS, Schwertfeger KL. Defining and targeting macrophage heterogeneity in the mammary gland and breast cancer. Cancer Med. 2024;13:e7053.
111. Hirano R, Okamoto K, Shinke M, et al. Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases. Commun Biol. 2023;6:144.
112. Wu K, Lin K, Li X, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020;11:1731.
113. Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6:75.
114. Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22:6995.
115. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593-604.
116. Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol. 2011;12:1035-44.
117. Griess B, Mir S, Datta K, Teoh-Fitzgerald M. Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat3 suppression. Free Radic Biol Med. 2020;147:48-60.
118. Chi J, Gao Q, Liu D. Tissue-resident macrophages in cancer: friend or foe? Cancer Med. 2024;13:e70387.
119. Roh MS, Wang L, Oyedeji C, et al. Human Kupffer cells are cytotoxic against human colon adenocarcinoma. Surgery. 1990;108:400-4.
120. Heuff G, van de Loosdrecht AA, Betjes MG, Beelen RH, Meijer S. Isolation and purification of large quantities of fresh human Kupffer cells, which are cytotoxic against colon carcinoma. Hepatology. 1995;21:740-5.
121. Kan Z, Ivancev K, Lunderquist A, McCuskey PA, McCuskey RS, Wallace S. In vivo microscopy of hepatic metastases: dynamic observation of tumor cell invasion and interaction with Kupffer cells. Hepatology. 1995;21:487-94.
122. Song E, Chen J, Ouyang N, Wang M, Exton MS, Heemann U. Kupffer cells of cirrhotic rat livers sensitize colon cancer cells to Fas-mediated apoptosis. Br J Cancer. 2001;84:1265-71.
123. Lau WY, Chen GG, Lai PB, et al. Induction of Fas and Fas ligand expression on malignant glioma cells by Kupffer cells, a potential pathway of antiliver metastases. J Surg Res. 2001;101:44-51.
124. Pearson HJ, Anderson J, Chamberlain J, Bell PR. The effect of Kupffer cell stimulation or depression on the development of liver metastases in the rat. Cancer Immunol Immunother. 1986;23:214-6.
125. Valatas V, Kolios G, Manousou P, et al. Secretion of inflammatory mediators by isolated rat Kupffer cells: the effect of octreotide. Regul Pept. 2004;120:215-25.
126. Aono K, Isobe K, Nakashima I, Kondo S, Miyachi M, Nimura Y. Kupffer cells cytotoxicity against hepatoma cells is related to nitric oxide. Biochem Biophys Res Commun. 1994;201:1175-81.
127. Hourani T, Holden JA, Li W, Lenzo JC, Hadjigol S, O’Brien-Simpson NM. Tumor associated macrophages: origin, recruitment, phenotypic diversity, and targeting. Front Oncol. 2021;11:788365.
128. Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA. The complex role of tumor-infiltrating macrophages. Nat Immunol. 2022;23:1148-56.
129. Tian Z, Hou X, Liu W, Han Z, Wei L. Macrophages and hepatocellular carcinoma. Cell Biosci. 2019;9:79.
130. Cotechini T, Atallah A, Grossman A. Tissue-resident and recruited macrophages in primary tumor and metastatic microenvironments: potential targets in cancer therapy. Cells. 2021;10:960.
131. Wu JY, Huang TW, Hsieh YT, et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol Cell. 2020;77:213-27.e5.
132. Casari M, Siegl D, Deppermann C, Schuppan D. Macrophages and platelets in liver fibrosis and hepatocellular carcinoma. Front Immunol. 2023;14:1277808.
133. Kuo TC, Chen A, Harrabi O, et al. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. J Hematol Oncol. 2020;13:160.
134. Deng Z, Loyher PL, Lazarov T, et al. The nuclear factor ID3 endows macrophages with a potent anti-tumour activity. Nature. 2024;626:864-73.
135. Brodt P. Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clin Cancer Res. 2016;22:5971-82.
136. Li J, Liu XG, Ge RL, et al. The ligation between ERMAP, galectin-9 and dectin-2 promotes Kupffer cell phagocytosis and antitumor immunity. Nat Immunol. 2023;24:1813-24.
137. Wortzel I, Seo Y, Akano I, et al. Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression. Nat Cancer. 2024;5:1815-33.
138. Jiang K, Chen H, Fang Y, et al. Exosomal ANGPTL1 attenuates colorectal cancer liver metastasis by regulating Kupffer cell secretion pattern and impeding MMP9 induced vascular leakiness. J Exp Clin Cancer Res. 2021;40:21.
139. Jin HR, Wang J, Wang ZJ, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16:103.
140. Ammarah U, Pereira-Nunes A, Delfini M, Mazzone M. From monocyte-derived macrophages to resident macrophages-how metabolism leads their way in cancer. Mol Oncol. 2024;18:1739-58.
141. Nagy C, Haschemi A. Time and demand are two critical dimensions of immunometabolism: the process of macrophage activation and the pentose phosphate pathway. Front Immunol. 2015;6:164.
142. Jha AK, Huang SC, Sergushichev A, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42:419-30.
144. Zaidi NE, Shazali NAH, Leow TC, Osman MA, Ibrahim K, Rahman NMANA. Crosstalk between fatty acid metabolism and tumour-associated macrophages in cancer progression. Biomedicine. 2022;12:9-19.
145. Liu Y, Xu R, Gu H, et al. Metabolic reprogramming in macrophage responses. Biomark Res. 2021;9:1.
146. Liu PS, Wang H, Li X, et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18:985-94.
147. Van den Bossche J, Lamers WH, Koehler ES, et al. Pivotal Advance: Arginase-1-independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes. J Leukoc Biol. 2012;91:685-99.
148. Van den Bossche J, O’Neill LA, Menon D. Macrophage Immunometabolism: where are we (going)? Trends Immunol. 2017;38:395-406.
149. Sharma A, Seow JJW, Dutertre CA, et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell. 2020;183:377-94.e21.
150. Casanova-Acebes M, Dalla E, Leader AM, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021;595:578-84.
151. Shen KY, Zhu Y, Xie SZ, Qin LX. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17:25.
152. Mass E, Ballesteros I, Farlik M, et al. Specification of tissue-resident macrophages during organogenesis. Science. 2016;353:aaf4238.
153. Li XY, Wang MY, Zhang JY, Li JZ, Gong JP, Zhang W. Kupffer cells suppress hepatocarcinogenesis and metastasis in tumor orthotopic implanted Kunming mice. Asian Pac J Cancer Prev. 2013;14:6393-8.
154. Hong GQ, Cai D, Gong JP, Lai X. Innate immune cells and their interaction with T cells in hepatocellular carcinoma. Oncol Lett. 2021;21:57.
155. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol. 2008;48:380-1.
156. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121-4.
157. Yuan Y, Wu D, Li J, et al. Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma. Front Pharmacol. 2023;14:1217400.
158. Lefere S, Degroote H, Van Vlierberghe H, Devisscher L. Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers. J Hepatol. 2019;71:631-3.
159. Degroote H, Lefere S, Vandierendonck A, et al. Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models. Oncotarget. 2021;12:562-77.
160. Bosco MC. Macrophage polarization: Reaching across the aisle? J Allergy Clin Immunol. 2019;143:1348-50.
161. Zhang Y, Han G, Gu J, Chen Z, Wu J. Role of tumor-associated macrophages in hepatocellular carcinoma: impact, mechanism, and therapy. Front Immunol. 2024;15:1429812.
162. Toledo B, Zhu Chen L, Paniagua-Sancho M, Marchal JA, Perán M, Giovannetti E. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J Hematol Oncol. 2024;17:44.
163. Wang Q, Ma W. Revisiting TAM polarization: beyond M1- and M2-type TAM toward clinical precision in macrophage-targeted therapy. Exp Mol Pathol. 2025;143:104982.
164. Yang Y, Ye YC, Chen Y, et al. Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors. Cell Death Dis. 2018;9:793.
165. Ma RY, Black A, Qian BZ. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022;43:546-63.
166. Guo S, Chen X, Guo C, Wang W. Tumour-associated macrophages heterogeneity drives resistance to clinical therapy. Expert Rev Mol Med. 2022;24:e17.
167. Li JQ, Yu XJ, Wang YC, et al. Distinct patterns and prognostic values of tumor-infiltrating macrophages in hepatocellular carcinoma and gastric cancer. J Transl Med. 2017;15:37.
168. Lu Y, Yang A, Quan C, et al. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat Commun. 2022;13:4594.
169. Xiao N, Zhu X, Li K, et al. Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma. Exp Hematol Oncol. 2021;10:36.
170. Ng HHM, Lee RY, Goh S, et al. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2020;8:e000987.
171. Cui X, Zhao H, Wei S, et al. Hepatocellular carcinoma-derived FOXO1 inhibits tumor progression by suppressing IL-6 secretion from macrophages. Neoplasia. 2023;40:100900.
172. Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 2012;72:3977-86.
173. Dou L, Shi X, He X, Gao Y. Macrophage phenotype and function in liver disorder. Front Immunol. 2019;10:3112.
174. Thomann S, Weiler SME, Wei T, et al. YAP-induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer. Liver Int. 2021;41:3011-23.
175. Vanderborght B, De Muynck K, Gijbels E, et al. Transient Kupffer cell depletion and subsequent replacement by infiltrating monocyte-derived cells does not alter the induction or progression of hepatocellular carcinoma. Int J Cancer. 2023;152:2615-28.
176. Du L, Ji Y, Xin B, et al. Shp2 deficiency in Kupffer cells and hepatocytes aggravates hepatocarcinogenesis by recruiting non-Kupffer macrophages. Cell Mol Gastroenterol Hepatol. 2023;15:1351-69.
177. Li X, Li R, Miao X, et al. Integrated single cell analysis reveals an atlas of tumor associated macrophages in hepatocellular carcinoma. Inflammation. 2024;47:2077-93.
178. Zhang M, Liu K, Zhang Q, et al. Alpha fetoprotein promotes polarization of macrophages towards M2-like phenotype and inhibits macrophages to phagocytize hepatoma cells. Front Immunol. 2023;14:1081572.
179. Yu H, Pan J, Zheng S, et al. Hepatocellular carcinoma cell-derived exosomal miR-21-5p induces macrophage M2 polarization by targeting RhoB. Int J Mol Sci. 2023;24:4593.
180. Sun JL, Zhang NP, Xu RC, et al. Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages. J Transl Med. 2021;19:347.
181. Yang S, Zhang J, Xu Y, et al. OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression. Cancer Immunol Immunother. 2022;71:2677-89.
182. Zhao J, Zhang S, Liu Y, et al. Single-cell RNA sequencing reveals the heterogeneity of liver-resident immune cells in human. Cell Discov. 2020;6:22.
183. Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184:404-21.e16.
184. Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179:829-45.e20.
185. Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor microenvironment of hepatocellular carcinoma: challenges and opportunities for new treatment options. Int J Mol Sci. 2022;23:3778.
186. Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:187204.
187. Yu M, Yu H, Wang H, et al. Tumor‑associated macrophages activated in the tumor environment of hepatocellular carcinoma: characterization and treatment (Review). Int J Oncol. 2024;65:100.
188. Ajith A, Evraerts J, Bouzin C, et al. Progression to fibrosis and hepatocellular carcinoma in DEN CCl4 liver mice, is associated with macrophage and striking regulatory T cells infiltration. Front Immunol 2025;16:1601215.[PMID:40698077 DOI:10.3389/fimmu.2025.1601215 PMCID:12279789] Caution!.
189. Malehmir M, Pfister D, Gallage S, et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med. 2019;25:641-55.
190. Roderburg C, Wree A, Demir M, Schmelzle M, Tacke F. The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepat Oncol. 2020;7:HEP17.
191. Chen J, Zheng DX, Yu XJ, et al. Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients. Oncoimmunology. 2019;8:e1652540.
192. Li YW, Qiu SJ, Fan J, et al. Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J Cancer Res Clin Oncol. 2009;135:439-49.
193. Zhang Y, Li JQ, Jiang ZZ, Li L, Wu Y, Zheng L. CD169 identifies an anti-tumour macrophage subpopulation in human hepatocellular carcinoma. J Pathol. 2016;239:231-41.
194. Ding T, Xu J, Wang F, et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol. 2009;40:381-9.
195. Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547-51.
196. Liu N, Wang X, Steer CJ, Song G. MicroRNA-206 promotes the recruitment of CD8+ T cells by driving M1 polarisation of Kupffer cells. Gut. 2022;71:1642-55.
197. Hastir JF, Delbauve S, Larbanoix L, et al. Hepatocarcinoma induces a tumor necrosis factor-dependent Kupffer cell death pathway that favors its proliferation upon partial hepatectomy. Front Oncol. 2020;10:547013.
198. Tian Y, Zhang M, Fan M, et al. A miRNA-mediated attenuation of hepatocarcinogenesis in both hepatocytes and Kupffer cells. Mol Ther Nucleic Acids. 2022;30:1-12.
199. Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82:2252-66.
200. Wu H, Zhong Z, Wang A, et al. LncRNA FTX represses the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via regulating the M1/M2 polarization of Kupffer cells. Cancer Cell Int. 2020;20:266.
201. Wei Q, Liu G, Huang Z, et al. LncRNA MEG3 inhibits tumor progression by modulating macrophage phenotypic polarization via miR-145-5p/DAB2 axis in hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:1019-35.
202. Hou ZH, Xu XW, Fu XY, Zhou LD, Liu SP, Tan DM. Long non-coding RNA MALAT1 promotes angiogenesis and immunosuppressive properties of HCC cells by sponging miR-140. Am J Physiol Cell Physiol. 2020;318:C649-63.
203. Tian X, Wu Y, Yang Y, et al. Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/β-catenin signaling. Mol Oncol. 2020;14:462-83.
204. Ye Y, Xu Y, Lai Y, et al. Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization. J Cell Biochem. 2018;119:2951-63.
205. Wang X, Li FY, Zhao W, et al. Long non-coding RNA GAS5 overexpression inhibits M2-like polarization of tumour-associated macrophages in SMCC-7721 cells by promoting PTEN expression. Int J Exp Pathol. 2020;101:215-22.
206. Xu M, Zhou C, Weng J, et al. Tumor associated macrophages-derived exosomes facilitate hepatocellular carcinoma malignance by transferring lncMMPA to tumor cells and activating glycolysis pathway. J Exp Clin Cancer Res. 2022;41:253.
207. Li X, Lei Y, Wu M, Li N. Regulation of macrophage activation and polarization by HCC-derived exosomal lncRNA TUC339. Int J Mol Sci. 2018;19:2958.
208. Lv S, Wang J, Li L. Extracellular vesicular lncRNA FAL1 promotes hepatocellular carcinoma cell proliferation and invasion by inducing macrophage M2 polarization. J Physiol Biochem. 2023;79:669-82.
209. Ai JH, Wen YZ, Dai SJ, Zhang LD, Huang ZJ, Shi J. Exosomal lncRNA HEIH, an essential communicator for hepatocellular carcinoma cells and macrophage M2 polarization through the miR-98-5p/STAT3 axis. J Biochem Mol Toxicol. 2024;38:e23686.
210. Wang X, Zhou Y, Dong K, Zhang H, Gong J, Wang S. Exosomal lncRNA HMMR-AS1 mediates macrophage polarization through miR-147a/ARID3A axis under hypoxia and affects the progression of hepatocellular carcinoma. Environ Toxicol. 2022;37:1357-72.
211. Zhou J, Che J, Xu L, Yang W, Zhou W, Zhou C. Tumor-derived extracellular vesicles containing long noncoding RNA PART1 exert oncogenic effect in hepatocellular carcinoma by polarizing macrophages into M2. Dig Liver Dis. 2022;54:543-53.
212. Ye Y, Wang M, Wang G, et al. lncRNA miR4458HG modulates hepatocellular carcinoma progression by activating m6A-dependent glycolysis and promoting the polarization of tumor-associated macrophages. Cell Mol Life Sci. 2023;80:99.
213. Zhao S, Chen F, Hu L, et al. Long non-coding rnas as key modulators of the immune microenvironment in hepatocellular carcinoma: implications for Immunotherapy. Front Immunol. 2025;16:1523190.
214. Ghorbani Vanan A, Nami MT, Ghorbaninezhad F, et al. Macrophage polarization in hepatocellular carcinoma: a lncRNA-centric perspective on tumor progression and metastasis. Clin Exp Med. 2025;25:173.
215. Delire B, Henriet P, Lemoine P, Leclercq IA, Stärkel P. Chronic liver injury promotes hepatocarcinoma cell seeding and growth, associated with infiltration by macrophages. Cancer Sci. 2018;109:2141-52.
216. Huang Y, Ge W, Zhou J, Gao B, Qian X, Wang W. The role of tumor associated macrophages in hepatocellular carcinoma. J Cancer. 2021;12:1284-94.
217. Chang CP, Su YC, Lee PH, Lei HY. Targeting NFKB by autophagy to polarize hepatoma-associated macrophage differentiation. Autophagy. 2013;9:619-21.
218. Sugisawa R, Komatsu G, Hiramoto E, et al. Independent modes of disease repair by AIM protein distinguished in AIM-felinized mice. Sci Rep. 2018;8:13157.
219. Zhang J, Pan Y, Zhao Z, et al. SLC16A3 as an immunosuppressive Kupffer cell marker predicts poor prognosis in HBV-positive hepatocellular carcinoma. J Transl Med. 2025;23:988.
220. Ohno A, Yorita K, Haruyama Y, et al. Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma. Liver Int. 2014;34:942-52.
221. Alves VA, Pinheiro C, Morais-Santos F, Felipe-Silva A, Longatto-Filho A, Baltazar F. Characterization of monocarboxylate transporter activity in hepatocellular carcinoma. World J Gastroenterol. 2014;20:11780-7.
222. Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab. 2016;27:84-95.
223. Escobedo-calvario A, Chávez-rodríguez L, Simoni-nieves A, et al. Tumor immune microenvironment modulation by cholesterol in hepatocellular carcinoma. Explor Dig Dis. 2022;1:21-39.
224. Simoni-Nieves A, Salas-Silva S, Chávez-Rodríguez L, et al. The consumption of cholesterol-enriched diets conditions the development of a subtype of HCC with high aggressiveness and poor prognosis. Cancers. 2021;13:1721.
225. Goossens P, Rodriguez-Vita J, Etzerodt A, et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019;29:1376-89.e4.
226. Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. 2025;44:145.
227. Sheng J, Zhang J, Wang L, et al. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. Gut. 2022;71:1176-91.
228. Liu W, Zhou X, Yao Q, et al. In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis. J Clin Invest. 2023;133:e157937.
229. Siwicki M, Gort-Freitas NA, Messemaker M, et al. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci Immunol. 2021;6:eabi7083.
230. Xu W, Cheng Y, Guo Y, Yao W, Qian H. Targeting tumor associated macrophages in hepatocellular carcinoma. Biochem Pharmacol. 2022;199:114990.
231. Giannone G, Ghisoni E, Genta S, et al. Immuno-metabolism and microenvironment in cancer: key players for immunotherapy. Int J Mol Sci. 2020;21:4414.
232. Lemaitre L, Adeniji N, Suresh A, et al. Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease. Nat Cancer. 2024;5:1534-56.
233. Weng J, Wang Z, Hu Z, et al. Repolarization of immunosuppressive macrophages by targeting SLAMF7-regulated CCL2 signaling sensitizes hepatocellular carcinoma to immunotherapy. Cancer Res. 2024;84:1817-33.
234. Zhang Y, Rao Y, Lu J, et al. The influence of biophysical niche on tumor-associated macrophages in liver cancer. Hepatol Commun. 2024;8:e0569.
235. Li M, He L, Zhu J, Zhang P, Liang S. Targeting tumor-associated macrophages for cancer treatment. Cell Biosci. 2022;12:85.
236. Liu X, Hogg GD, Zuo C, et al. Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer Cell. 2023;41:1073-90.e12.
237. Liu F, Li X, Zhang Y, et al. Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma. J Exp Clin Cancer Res. 2025;44:227.
238. Chen M, Lai R, Lin X, Chen W, Wu H, Zheng Q. Downregulation of triggering receptor expressed on myeloid cells 1 inhibits invasion and migration of liver cancer cells by mediating macrophage polarization. Oncol Rep. 2021;45:37.
239. Yang Y, Jia X, Qu M, et al. Exploring the potential of treating chronic liver disease targeting the PI3K/Akt pathway and polarization mechanism of macrophages. Heliyon. 2023;9:e17116.
240. Ren L, Qiao GL, Zhang SX, Zhang ZM, Lv SX. Pharmacological inhibition or silencing of TREM1 restrains HCC cell metastasis by inactivating TLR/PI3K/AKT signaling. Cell Biochem Biophys. 2024;82:2673-85.
241. Song M, Li ZH, Gu HS, et al. Ganoderma lucidum spore polysaccharide inhibits the growth of hepatocellular carcinoma cells by altering macrophage polarity and induction of apoptosis. J Immunol Res. 2021;2021:6696606.
242. Lu S, Gao Y, Huang X, Wang X. Cantharidin exerts anti-hepatocellular carcinoma by miR-214 modulating macrophage polarization. Int J Biol Sci. 2014;10:415-25.
243. Min L, Wang H, Qi H. Astragaloside IV inhibits the progression of liver cancer by modulating macrophage polarization through the TLR4/NF-κB/STAT3 signaling pathway. Am J Transl Res. 2022;14:1551-66.
244. Bannister ME, Chatterjee DA, Shetty S, Patten DA. The role of macrophages in hepatocellular carcinoma and their therapeutic potential. Int J Mol Sci. 2024;25:13167.
245. Cancer Genome Atlas Research Network. Electronic address: [email protected]; Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327-41.e23.
246. Cai N, Cheng K, Ma Y, et al. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy. Gut. 2024;73:985-99.
247. Zhao J, Cui M, Yao X, et al. Targeting TFAM downregulation mediated mtDNA-NLRP3 pathway suppresses TAM infiltration and HCC progression. Oncogene. 2025;44:2956-69.
248. Zhu CX, Yan K, Chen L, et al. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8+ T cells in hepatocellular carcinoma. J Hepatol. 2024;81:690-703.
249. Fu X, Pang M, Wang Z, Wang H. Macrophage polarization in the tumor microenvironment of hepatocellular carcinoma: from mechanistic insights to translational therapies. Cancer Control. 2025;32:10732748251406674.
250. Tan J, Fan W, Liu T, et al. TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023;79:126-40.
251. Yang H, Zhang Z, Zhao K, et al. Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy. Hum Immunol. 2024;85:110774.
252. Karimova AF, Khalitova AR, Suezov R, et al. Immunometabolism of tumor-associated macrophages: a therapeutic perspective. Eur J Cancer. 2025;220:115332.
253. Li D, Rudloff U. Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers. Expert Opin Emerg Drugs. 2025;30:109-47.
254. Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021;6:127.
255. Yang S, Wang Y, Jia J, et al. Advances in engineered macrophages: a new frontier in cancer immunotherapy. Cell Death Dis. 2024;15:238.
256. Na YR, Kim SW, Seok SH. A new era of macrophage-based cell therapy. Exp Mol Med. 2023;55:1945-54.
257. Etzerodt A, Tsalkitzi K, Maniecki M, et al. Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. J Exp Med. 2019;216:2394-411.
